Portal de Periódicos da CAPES

Assessment of antigenic difference of equine influenza virus strains by challenge study in horses

2016; Wiley; Volume: 10; Issue: 6 Linguagem: Inglês

10.1111/irv.12418

1750-2659

Takashi Yamanaka, Manabu Nemoto, Hiroshi Bannai, Koji Tsujimura, Takashi Kondo, Tomio Matsumura, Sarah Gildea, Ann Cullinane,

Immune Response and Inflammation

We previously reported that horse antiserum against the Japanese equine influenza vaccine virus, A/equine/La Plata/1993 (LP93) exhibited reduced cross-neutralization against some Florida sublineage Clade (Fc) 2 viruses, for example, A/equine/Carlow/2011 (CL11). As a result, Japanese vaccine manufacturers will replace LP93 with A/equine/Yokohama/aq13/2010 (Y10, Fc2). To assess the benefit of updating the vaccine, five horses vaccinated with inactivated Y10 vaccine and five vaccinated with inactivated LP93 were challenged by exposure to a nebulized aerosol of CL11. The durations of pyrexia (≥38.5°C) and other adverse clinical symptoms experienced by the Y10 group were significantly shorter than those of the LP93 group.